Table 1.
Total study population n = 40 |
Patients with a blood sample at 6 months n = 15 |
Patients without a blood sample at 6 months n = 25 |
p value | |
---|---|---|---|---|
Age (years), median (IQR) | 68 (58–77) | 62 (48–72) | 71 (62–78) | 0.08 |
Male gender, n (%) | 21 (52.5) | 8 (53.3) | 13 (52.0) | 1 |
SOFA score on day 1–2, median (IQR) | 8 (7–9) | 9 (7–10) | 7 (6–9) | 0.38 |
SAPS II, median (IQR) | 53 (43–66) | 52 (48–62) | 53 (42–69) | 0.71 |
Maximum lactate (mmol/L), median (IQR) | 2.7 (1.8–3.7) | 3.5 (2.5–5.9) | 2.4 (1.7–2.9) | 0.37 |
Missing data, n | 3 | 3 | ||
Comorbidities, n (%) | ||||
Chronic arterial hypertension | 21 (52.5) | 6 (40.0) | 15 (60.0) | 0.32 |
Chronic heart failure | 6 (15.0) | 1 (6.7) | 5 (20.0) | 0.38 |
Myocardial infarction | 3 (7.5) | 1 (6.7) | 2 (8.0) | 1 |
Stroke | 2 (5.0) | 1 (6.7) | 1 (4.0) | 1 |
Chronic obstructive pulmonary disease | 9 (22.5) | 2 (13.3) | 7 (28.0) | 0.44 |
Dialysis-dependent chronic kidney disease | 1 (2.5) | 0 | 1 (4.0) | 1 |
Liver cirrhosis | 0 | 0 | 0 | 1 |
Diabetes mellitus | 8 (20.0) | 0 | 8 (32.0) | 0.01 |
Source of infection, n (%) | ||||
Abdominal | 20 (50.0) | 6 (40.0) | 14 (56.0) | 0.51 |
Skin and soft tissue | 7 (17.5) | 1 (6.7) | 6 (24.0) | 0.22 |
Respiratory | 5 (12.5) | 2 (13.3) | 3 (12.0) | 1 |
Stomatological | 3 (7.5) | 3 (20.0) | 0 | 0.04 |
Urinary tract | 3 (7.5) | 2 (13.3) | 1 (4.0) | 0.54 |
Osteoarticular | 2 (5.0) | 1 (6.7) | 1 (4.0) | 1 |
General management, n (%) | ||||
Surgery | 33 (82.5) | 13 (86.7) | 20 (80.0) | 0.69 |
Medical only | 7 (17.5) | 2 (13.3) | 5 (20.0) | 0.69 |
Support measures, n (%) | ||||
Norepinephrine | 40 (100.0) | 15 (100.0) | 25 (100.0) | 1 |
Dobutamine | 5 (12.5) | 1 (6.7) | 4 (16.0) | 0.63 |
Mechanical ventilation | 31 (77.5) | 11 (73.3) | 20 (80.0) | 0.70 |
Renal replacement therapy | 12 (30.0) | 4 (26.7) | 8 (32.0) | 1 |
Outcomes (days), median (IQR) | ||||
Days on vasopressors | 4 (3–5) | 4 (3–10) | 3 (2–5) | 0.30 |
Days on mechanical ventilation | 6 (3–8) | 7 (4–9) | 5 (2–7) | 0.43 |
Patients involved, n | 31 | 11 | 20 | |
Days on renal replacement therapy | 8 (6–8) | 10 (8–12) | 7 (4–8) | 0.05 |
Patients involved, n | 12 | 4 | 8 | |
ICU length of stay | 11 (7–24) | 13 (6–25) | 10 (7–24) | 0.86 |
Hospital length of stay | 37 (16–48) | 37 (19–46) | 37 (19–49) | 0.75 |
IQR interquartile range, SOFA Sepsis-related Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, ICU intensive care unit